{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T21:59:48Z","timestamp":1791496788057,"version":"4.3.4"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2026,2,11]],"date-time":"2026-02-11T00:00:00Z","timestamp":1770768000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,2,11]],"date-time":"2026-02-11T00:00:00Z","timestamp":1770768000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82272753"],"award-info":[{"award-number":["82272753"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007129","name":"Natural Science Foundation of Shandong Province","doi-asserted-by":"publisher","award":["ZR2021LZL002"],"award-info":[{"award-number":["ZR2021LZL002"]}],"id":[{"id":"10.13039\/501100007129","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100014103","name":"Key Technology Research and Development Program of Shandong Province","doi-asserted-by":"publisher","award":["2021SFGC05012021"],"award-info":[{"award-number":["2021SFGC05012021"]}],"id":[{"id":"10.13039\/100014103","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Nucl Med Mol Imaging"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1007\/s00259-026-07804-7","type":"journal-article","created":{"date-parts":[[2026,2,11]],"date-time":"2026-02-11T07:18:19Z","timestamp":1770794299000},"page":"3877-3890","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Assessment of liver fibrosis and tumor burden in hepatocellular carcinoma using [18F]AlF-NOTA-FAPI-04 PET\/CT: a prospective study"],"prefix":"10.1007","volume":"53","author":[{"given":"Chen","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ke","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wanhu","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kunli","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xue","family":"Dou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuxin","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yumeng","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiang","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5242-6554","authenticated-orcid":false,"given":"Jinbo","family":"Yue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,2,11]]},"reference":[{"key":"7804_CR1","doi-asserted-by":"publisher","first-page":"229","DOI":"10.3322\/caac.21834","volume":"74","author":"F Bray","year":"2024","unstructured":"Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024;74:229\u201363. https:\/\/doi.org\/10.3322\/caac.21834.","journal-title":"CA Cancer J Clin"},{"key":"7804_CR2","doi-asserted-by":"publisher","first-page":"1301","DOI":"10.1016\/S0140-6736(18)30010-2","volume":"391","author":"A Forner","year":"2018","unstructured":"Forner A, Reig M, Bruix J. Hepatocellular carcinoma. Lancet. 2018;391:1301\u201314. https:\/\/doi.org\/10.1016\/S0140-6736(18)30010-2.","journal-title":"Lancet"},{"key":"7804_CR3","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1002\/hep.29913","volume":"68","author":"JA Marrero","year":"2018","unstructured":"Marrero JA, Kulik LM, Sirlin CB, Zhu AX, Finn RS, Abecassis MM, et al. Diagnosis, staging, and management of hepatocellular carcinoma: 2018 practice guidance by the American Association for the Study of Liver Diseases. Hepatology. 2018;68:723\u201350. https:\/\/doi.org\/10.1002\/hep.29913.","journal-title":"Hepatology"},{"key":"7804_CR4","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1016\/j.cgh.2017.10.001","volume":"16","author":"ND Parikh","year":"2018","unstructured":"Parikh ND, Scaglione S, Li Y, Powell C, Yerokun OA, Devlin P, et al. <article-title update=\"added\">A comparison of staging systems for hepatocellular carcinoma\u00a0in a multicenter US cohort. Clin Gastroenterol Hepatol. 2018;16:781\u20132. https:\/\/doi.org\/10.1016\/j.cgh.2017.10.001.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"7804_CR5","doi-asserted-by":"publisher","first-page":"890","DOI":"10.1111\/apt.16563","volume":"54","author":"E Harding\u2010Theobald","year":"2021","unstructured":"Harding\u2010Theobald E, Louissaint J, Maraj B, Cuaresma E, Townsend W, Mendiratta\u2010Lala M, et al. Systematic review: radiomics for the diagnosis and prognosis of hepatocellular carcinoma. Aliment Pharmacol Ther. 2021;54:890\u2013901. https:\/\/doi.org\/10.1111\/apt.16563.","journal-title":"Aliment Pharmacol Ther"},{"key":"7804_CR6","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1016\/j.jhep.2022.01.023","volume":"77","author":"AG Singal","year":"2022","unstructured":"Singal AG, Zhang E, Narasimman M, Rich NE, Waljee AK, Hoshida Y, et al. HCC surveillance improves early detection, curative treatment receipt, and survival in patients with cirrhosis: a meta-analysis. J Hepatol. 2022;77:128\u201339. https:\/\/doi.org\/10.1016\/j.jhep.2022.01.023.","journal-title":"J Hepatol"},{"key":"7804_CR7","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1007\/s00535-013-0790-5","volume":"49","author":"M Tsurusaki","year":"2014","unstructured":"Tsurusaki M, Okada M, Kuroda H, Matsuki M, Ishii K, Murakami T. Clinical application of 18F-fluorodeoxyglucose positron emission tomography for assessment and evaluation after therapy for malignant hepatic tumor. J Gastroenterol. 2014;49:46\u201356. https:\/\/doi.org\/10.1007\/s00535-013-0790-5.","journal-title":"J Gastroenterol"},{"key":"7804_CR8","doi-asserted-by":"publisher","first-page":"1912","DOI":"10.2967\/jnumed.108.055087","volume":"49","author":"J-W Park","year":"2008","unstructured":"Park J-W, Kim JH, Kim SK, Kang KW, Park KW, Choi J-I, et al. <article-title update=\"added\"> A prospective evaluation of 18 F-FDG and 11 C-Acetate PET\/CT for detection of primary and metastatic hepatocellular carcinoma. J Nucl Med. 2008;49:1912\u201321. https:\/\/doi.org\/10.2967\/jnumed.108.055087.","journal-title":"J Nucl Med"},{"key":"7804_CR9","doi-asserted-by":"publisher","first-page":"1285","DOI":"10.1007\/s00259-006-0164-9","volume":"33","author":"J-N Talbot","year":"2006","unstructured":"Talbot J-N, Gutman F, Fartoux L, Grange J-D, Ganne N, Kerrou K, et al. PET\/CT in patients with hepatocellular carcinoma using [18F]fluorocholine: preliminary comparison with [18F]FDG PET\/CT. Eur J Nucl Med Mol Imaging. 2006;33:1285\u20139. https:\/\/doi.org\/10.1007\/s00259-006-0164-9.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"7804_CR10","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1016\/j.jhep.2018.02.018","volume":"69","author":"J Chalaye","year":"2018","unstructured":"Chalaye J, Costentin CE, Luciani A, Amaddeo G, Ganne-Carri\u00e9 N, Baranes L, et al. Positron emission tomography\/computed tomography with 18F-fluorocholine improve tumor staging and treatment allocation in patients with hepatocellular carcinoma. J Hepatol. 2018;69:336\u201344. https:\/\/doi.org\/10.1016\/j.jhep.2018.02.018.","journal-title":"J Hepatol"},{"key":"7804_CR11","doi-asserted-by":"publisher","first-page":"1597","DOI":"10.2967\/jnumed.124.268147","volume":"65","author":"AJ Poot","year":"2024","unstructured":"Poot AJ, Lapa C, Weber WA, Lam MGEH, Eiber M, Dierks A, et al. [68 Ga]Ga-RAYZ-8009: a glypican-3\u2013targeted diagnostic radiopharmaceutical for hepatocellular carcinoma molecular imaging\u2014a first-in-human case series. J Nucl Med. 2024;65:1597\u2013603. https:\/\/doi.org\/10.2967\/jnumed.124.268147.","journal-title":"J Nucl Med"},{"key":"7804_CR12","doi-asserted-by":"publisher","unstructured":"Lin Z, Li M, Pan Z, Hu W, Feng Y, Zhang X, et al. Glypican-3\u2013targeted PET imaging for precise diagnosis of hepatocellular carcinoma: from bench to bedside. Clin Cancer Res. 2025;OF1\u201312. https:\/\/doi.org\/10.1158\/1078-0432.CCR-25-1856","DOI":"10.1158\/1078-0432.CCR-25-1856"},{"key":"7804_CR13","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1016\/j.jcmgh.2022.12.005","volume":"15","author":"A-T Yang","year":"2023","unstructured":"Yang A-T, Kim Y-O, Yan X-Z, Abe H, Aslam M, Park K-S, et al. Fibroblast activation protein activates macrophages and promotes parenchymal liver inflammation and fibrosis. Cell Mol Gastroenterol Hepatol. 2023;15:841\u201367. https:\/\/doi.org\/10.1016\/j.jcmgh.2022.12.005.","journal-title":"Cell Mol Gastroenterol Hepatol"},{"key":"7804_CR14","doi-asserted-by":"publisher","first-page":"711","DOI":"10.2967\/jnumed.122.264689","volume":"64","author":"N Hirmas","year":"2023","unstructured":"Hirmas N, Hamacher R, Sraieb M, Ingenwerth M, Kessler L, Pabst KM, et al. Fibroblast-activation protein PET and histopathology in a single-center database of 324 patients and 21 tumor entities. J Nucl Med. 2023;64:711\u20136. https:\/\/doi.org\/10.2967\/jnumed.122.264689.","journal-title":"J Nucl Med"},{"key":"7804_CR15","doi-asserted-by":"publisher","DOI":"10.3390\/ijms26051978","volume":"26","author":"RB Henrar","year":"2025","unstructured":"Henrar RB, Vuijk FA, Burchell GL, Van Dieren S, De Geus-Oei L-F, Kazemier G, et al. Diagnostic performance of radiolabelled FAPI versus [18F]FDG PET imaging in hepato-pancreato-biliary oncology: a systematic review and meta-analysis. Int J Mol Sci. 2025;26:1978. https:\/\/doi.org\/10.3390\/ijms26051978.","journal-title":"Int J Mol Sci"},{"key":"7804_CR16","doi-asserted-by":"publisher","first-page":"1593","DOI":"10.1007\/s00259-020-05070-9","volume":"48","author":"X Shi","year":"2021","unstructured":"Shi X, Xing H, Yang X, Li F, Yao S, Congwei J, et al. Comparison of PET imaging of activated fibroblasts and 18F-FDG for diagnosis of primary hepatic tumours: a prospective pilot study. Eur J Nucl Med Mol Imaging. 2021;48:1593\u2013603. https:\/\/doi.org\/10.1007\/s00259-020-05070-9.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"7804_CR17","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1007\/s00259-020-04882-z","volume":"48","author":"X Shi","year":"2021","unstructured":"Shi X, Xing H, Yang X, Li F, Yao S, Zhang H, et al. Fibroblast imaging of hepatic carcinoma with 68Ga-FAPI-04 PET\/CT: a pilot study in patients with suspected hepatic nodules. Eur J Nucl Med Mol Imaging. 2021;48:196\u2013203. https:\/\/doi.org\/10.1007\/s00259-020-04882-z.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"7804_CR18","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1146\/annurev-pathol-052016-100322","volume":"12","author":"S Affo","year":"2017","unstructured":"Affo S, Yu L-X, Schwabe RF. The role of cancer-associated fibroblasts and fibrosis in liver cancer. Annu Rev Pathol Mech Dis. 2017;12:153\u201386. https:\/\/doi.org\/10.1146\/annurev-pathol-052016-100322.","journal-title":"Annu Rev Pathol Mech Dis"},{"key":"7804_CR19","doi-asserted-by":"publisher","DOI":"10.1148\/radiol.222448","volume":"307","author":"D Peng","year":"2023","unstructured":"Peng D, Cao J, Guo C, He J, Yang L, Zhang J, et al. Influence of cirrhosis on68 Ga-FAPI PET\/CT in intrahepatic tumors. Radiology. 2023;307:e222448. https:\/\/doi.org\/10.1148\/radiol.222448.","journal-title":"Radiology"},{"key":"7804_CR20","doi-asserted-by":"publisher","first-page":"1532","DOI":"10.2967\/jnumed.123.265712","volume":"64","author":"M Wu","year":"2023","unstructured":"Wu M, Wang Y, Yang Q, Wang X, Yang X, Xing H, et al. Comparison of baseline68 Ga-FAPI and18 F-FDG PET\/CT for prediction of response and clinical outcome in patients with unresectable hepatocellular carcinoma treated with PD-1 inhibitor and lenvatinib. J Nucl Med. 2023;64:1532\u20139. https:\/\/doi.org\/10.2967\/jnumed.123.265712.","journal-title":"J Nucl Med"},{"key":"7804_CR21","doi-asserted-by":"publisher","DOI":"10.1148\/radiol.222785","volume":"308","author":"Y Wei","year":"2023","unstructured":"Wei Y, Ma L, Li P, Lu J, Ren J, Yan S, et al. FAPI compared with FDG PET\/CT for diagnosis of primary and metastatic lung cancer. Radiology. 2023;308:e222785. https:\/\/doi.org\/10.1148\/radiol.222785.","journal-title":"Radiology"},{"key":"7804_CR22","doi-asserted-by":"publisher","first-page":"201","DOI":"10.2967\/jnumed.120.245084","volume":"62","author":"FL Giesel","year":"2021","unstructured":"Giesel FL, Adeberg S, Syed M, Lindner T, Jim\u00e9nez-Franco LD, Mavriopoulou E, et al. FAPI-74 PET\/CT using either18 F-AlF or cold-Kit68 Ga labeling: biodistribution, radiation dosimetry, and tumor delineation in lung cancer patients. J Nucl Med. 2021;62:201\u20137. https:\/\/doi.org\/10.2967\/jnumed.120.245084.","journal-title":"J Nucl Med"},{"key":"7804_CR23","doi-asserted-by":"publisher","first-page":"2761","DOI":"10.1007\/s00259-022-05758-0","volume":"49","author":"Y Wei","year":"2022","unstructured":"Wei Y, Zheng J, Ma L, Liu X, Xu S, Wang S, et al. [18F]AlF-NOTA-FAPI-04: fap-targeting specificity, biodistribution, and PET\/CT imaging of various cancers. Eur J Nucl Med Mol Imaging. 2022;49:2761\u201373. https:\/\/doi.org\/10.1007\/s00259-022-05758-0.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"7804_CR24","doi-asserted-by":"publisher","first-page":"937","DOI":"10.1007\/s00259-022-06022-1","volume":"50","author":"J Zhang","year":"2023","unstructured":"Zhang J, He Q, Jiang S, Li M, Xue H, Zhang D, et al. [18F]FAPI PET\/CT in the evaluation of focal liver lesions with [18F]FDG non-avidity. Eur J Nucl Med Mol Imaging. 2023;50:937\u201350. https:\/\/doi.org\/10.1007\/s00259-022-06022-1.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"7804_CR25","doi-asserted-by":"publisher","first-page":"3572","DOI":"10.1007\/s00259-024-06773-z","volume":"51","author":"Y Song","year":"2024","unstructured":"Song Y, Qin C, Chen Y, Ruan W, Gai Y, Song W, et al. Non-invasive visualization of liver fibrosis with [68Ga]Ga-DOTA-FAPI-04 PET from preclinical insights to clinical translation. Eur J Nucl Med Mol Imaging. 2024;51:3572\u201384. https:\/\/doi.org\/10.1007\/s00259-024-06773-z.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"7804_CR26","doi-asserted-by":"publisher","first-page":"1604","DOI":"10.1007\/s00259-020-05095-0","volume":"48","author":"W Guo","year":"2021","unstructured":"Guo W, Pang Y, Yao L, Zhao L, Fan C, Ke J, et al. Imaging fibroblast activation protein in liver cancer: a single-center post hoc retrospective analysis to compare [68Ga]Ga-FAPI-04 PET\/CT versus MRI and [18F]-FDG PET\/CT. Eur J Nucl Med Mol Imaging. 2021;48:1604\u201317. https:\/\/doi.org\/10.1007\/s00259-020-05095-0.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"7804_CR27","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-024-07062-5","author":"D Zhu","year":"2025","unstructured":"Zhu D, Song S, Zou S, Kuang D, Wang D, Min X, et al. Assessment of viable tumours by [68Ga]Ga-FAPI-04 PET\/CT after local regional treatment in patients with hepatocellular carcinoma. Eur J Nucl Med Mol Imaging. 2025. https:\/\/doi.org\/10.1007\/s00259-024-07062-5.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"7804_CR28","doi-asserted-by":"publisher","first-page":"1956","DOI":"10.2967\/jnumed.121.263736","volume":"63","author":"A Pirasteh","year":"2022","unstructured":"Pirasteh A, Periyasamy S, Meudt JJ, Liu Y, Lee LM, Schachtschneider KM, et al. Staging liver fibrosis by fibroblast activation protein inhibitor PET in a human-sized swine model. J Nucl Med. 2022;63:1956\u201361. https:\/\/doi.org\/10.2967\/jnumed.121.263736.","journal-title":"J Nucl Med"},{"key":"7804_CR29","doi-asserted-by":"publisher","DOI":"10.1186\/s40644-023-00626-y","volume":"23","author":"J Zhang","year":"2023","unstructured":"Zhang J, Jiang S, Li M, Xue H, Zhong X, Li S, et al. Head-to-head comparison of 18F-FAPI and 18F-FDG PET\/CT in staging and therapeutic management of hepatocellular carcinoma. Cancer Imaging. 2023;23:106. https:\/\/doi.org\/10.1186\/s40644-023-00626-y.","journal-title":"Cancer Imaging"},{"key":"7804_CR30","doi-asserted-by":"publisher","DOI":"10.3390\/ijms25137197","volume":"25","author":"F Manuppella","year":"2024","unstructured":"Manuppella F, Pisano G, Taralli S, Caldarella C, Calcagni ML. Diagnostic performances of PET\/CT using fibroblast activation protein inhibitors in patients with primary and metastatic liver tumors: a comprehensive literature review. Int J Mol Sci. 2024;25:7197. https:\/\/doi.org\/10.3390\/ijms25137197.","journal-title":"Int J Mol Sci"},{"key":"7804_CR31","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.693640","volume":"11","author":"H Wang","year":"2021","unstructured":"Wang H, Zhu W, Ren S, Kong Y, Huang Q, Zhao J, et al. 68Ga-FAPI-04 versus 18F-FDG PET\/CT in the detection of hepatocellular carcinoma. Front Oncol. 2021;11:693640. https:\/\/doi.org\/10.3389\/fonc.2021.693640.","journal-title":"Front Oncol"},{"key":"7804_CR32","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-021-01428-1","volume":"20","author":"X Mao","year":"2021","unstructured":"Mao X, Xu J, Wang W, Liang C, Hua J, Liu J, et al. Crosstalk between cancer-associated fibroblasts and immune cells in the tumor microenvironment: new findings and future perspectives. Mol Cancer. 2021;20:131. https:\/\/doi.org\/10.1186\/s12943-021-01428-1.","journal-title":"Mol Cancer"},{"key":"7804_CR33","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.2967\/jnumed.121.262426","volume":"63","author":"CE Mona","year":"2022","unstructured":"Mona CE, Benz MR, Hikmat F, Grogan TR, Lueckerath K, Razmaria A, et al. Correlation of68 Ga-FAPi-46 PET biodistribution with FAP expression by immunohistochemistry in patients with solid cancers: interim analysis of a prospective translational exploratory study. J Nucl Med. 2022;63:1021\u20136. https:\/\/doi.org\/10.2967\/jnumed.121.262426.","journal-title":"J Nucl Med"},{"key":"7804_CR34","doi-asserted-by":"publisher","first-page":"52","DOI":"10.2967\/jnumed.123.266393","volume":"65","author":"A-M Spektor","year":"2024","unstructured":"Spektor A-M, Gutjahr E, Lang M, Glatting FM, Hackert T, Pausch T, et al. Immunohistochemical FAP expression reflects68 Ga-FAPI PET imaging properties of low- and high-grade intraductal papillary mucinous neoplasms and pancreatic ductal adenocarcinoma. J Nucl Med. 2024;65:52\u20138. https:\/\/doi.org\/10.2967\/jnumed.123.266393.","journal-title":"J Nucl Med"},{"key":"7804_CR35","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1007\/s00259-024-06873-w","volume":"52","author":"T Liu","year":"2024","unstructured":"Liu T, Xu S, Cheng K, Pei J, Wang S, Li C, et al. Exploring the value of FAP-targeted PET\/CT in differentiating breast cancer molecular subtypes: a preliminary study. Eur J Nucl Med Mol Imaging. 2024;52:280\u201390. https:\/\/doi.org\/10.1007\/s00259-024-06873-w.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"7804_CR36","doi-asserted-by":"publisher","first-page":"6935","DOI":"10.7150\/thno.103399","volume":"14","author":"J Sun","year":"2024","unstructured":"Sun J, Han C, Cai J, Yu L, Zhao L, Pang Y, et al. 68 Ga-FAPI-46 PET\/CT in the evaluation of gliomas: comparison with18 F-FDG PET\/CT and contrast-enhanced MRI. Theranostics. 2024;14:6935\u201346. https:\/\/doi.org\/10.7150\/thno.103399.","journal-title":"Theranostics"},{"key":"7804_CR37","doi-asserted-by":"publisher","DOI":"10.1186\/s13046-021-01914-w","author":"W Huang","year":"2021","unstructured":"Huang W, Zhang L, Yang M, Wu X, Wang X, Huang W, et al. Correction to: cancer-associated fibroblasts promote the survival of irradiated nasopharyngeal carcinoma cells via the NF-\u03baB pathway. J Exp Clin Cancer Res. 2021. https:\/\/doi.org\/10.1186\/s13046-021-01914-w.","journal-title":"J Exp Clin Cancer Res"},{"key":"7804_CR38","doi-asserted-by":"publisher","first-page":"4822","DOI":"10.7150\/thno.99046","volume":"14","author":"F Long","year":"2024","unstructured":"Long F, Zhong W, Zhao F, Xu Y, Hu X, Jia G, et al. DAB2+ macrophages support FAP+ fibroblasts in shaping tumor barrier and inducing poor clinical outcomes in liver cancer. Theranostics. 2024;14:4822\u201343. https:\/\/doi.org\/10.7150\/thno.99046.","journal-title":"Theranostics"},{"key":"7804_CR39","doi-asserted-by":"publisher","first-page":"2157","DOI":"10.1007\/s00259-025-07093-6","volume":"52","author":"E Lin","year":"2025","unstructured":"Lin E, Song M, Wang B, Shi X, Zhao J, Fu L, et al. Fibroblast activation protein peptide-targeted NIR-I\/II fluorescence imaging for stable and functional detection of hepatocellular carcinoma. Eur J Nucl Med Mol Imaging. 2025;52:2157\u201370. https:\/\/doi.org\/10.1007\/s00259-025-07093-6.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"7804_CR40","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41421-024-00747-z","volume":"11","author":"Y Cheng","year":"2025","unstructured":"Cheng Y, Chen X, Feng L, Yang Z, Xiao L, Xiang B, et al. Stromal architecture and fibroblast subpopulations with opposing effects on outcomes in hepatocellular carcinoma. Cell Discovery. 2025;11:1\u201325. https:\/\/doi.org\/10.1038\/s41421-024-00747-z.","journal-title":"Cell Discovery"}],"container-title":["European Journal of Nuclear Medicine and Molecular Imaging"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-026-07804-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00259-026-07804-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-026-07804-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,27]],"date-time":"2026-04-27T07:26:20Z","timestamp":1777274780000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00259-026-07804-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,11]]},"references-count":40,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["7804"],"URL":"https:\/\/doi.org\/10.1007\/s00259-026-07804-7","relation":{},"ISSN":["1619-7070","1619-7089"],"issn-type":[{"value":"1619-7070","type":"print"},{"value":"1619-7089","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,11]]},"assertion":[{"value":"6 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by the local ethics committee of Shandong Cancer Hospital (SDTHEC202412014), and all participants provided written informed consent. The study was conducted in accordance with the Helsinki Declaration and ethical standards. Consent for the inclusion of data and images in this publication was obtained from all participants or their legal guardians, including for online open-access publication.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Informed consent was obtained from all individual participants included in the study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"All authors have reviewed and approved the final version of the manuscript for submission and publication. Consent has been obtained from all participants whose data or images are included in the study, ensuring compliance with ethical guidelines. No identifiable personal information or data of participants has been included in this manuscript.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}